Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Buy” by Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $11.40.

RVPH has been the subject of several recent analyst reports. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, January 10th. HC Wainwright decreased their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. Finally, Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th.

Reviva Pharmaceuticals Stock Performance

RVPH opened at $2.02 on Wednesday. The company has a fifty day moving average of $1.81 and a two-hundred day moving average of $1.37. The stock has a market capitalization of $67.55 million, a price-to-earnings ratio of -1.82 and a beta of -0.12. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $4.83.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of hedge funds have recently modified their holdings of RVPH. Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after purchasing an additional 42,376 shares during the last quarter. Drive Wealth Management LLC purchased a new position in Reviva Pharmaceuticals during the fourth quarter worth approximately $36,000. Finally, EMC Capital Management boosted its stake in Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after buying an additional 26,134 shares during the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.